Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

References for PMC Articles for PubMed (Select 22457633)

1.

APOBEC3 has not left an evolutionary footprint on the HIV-1 genome.

Ebrahimi D, Anwar F, Davenport MP.

J Virol. 2011 Sep;85(17):9139-46. doi: 10.1128/JVI.00658-11. Epub 2011 Jun 22.

2.

Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis.

Hauser A, Mugenyi K, Kabasinguzi R, Kuecherer C, Harms G, Kunz A.

PLoS One. 2011;6(5):e20357. doi: 10.1371/journal.pone.0020357. Epub 2011 May 31.

3.

Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing.

D'Aquila RT, Geretti AM, Horton JH, Rouse E, Kheshti A, Raffanti S, Oie K, Pappa K, Ross LL.

AIDS Res Hum Retroviruses. 2011 Feb;27(2):201-9. doi: 10.1089/aid.2010.0077. Epub 2010 Oct 7.

PMID:
20929395
4.

Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.

Fourati S, Malet I, Binka M, Boukobza S, Wirden M, Sayon S, Simon A, Katlama C, Simon V, Calvez V, Marcelin AG.

AIDS. 2010 Sep 24;24(15):2313-21. doi: 10.1097/QAD.0b013e32833e515a.

PMID:
20729708
5.

Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.

Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, Malim MH, Wolinsky SM.

J Virol. 2010 Oct;84(19):10402-5. doi: 10.1128/JVI.01223-10. Epub 2010 Jul 21.

6.

Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.

Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, Harari A, Kunz A, Simon V.

J Virol. 2010 Sep;84(18):9613-7. doi: 10.1128/JVI.02630-09. Epub 2010 Jun 30.

7.

APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Sadler HA, Stenglein MD, Harris RS, Mansky LM.

J Virol. 2010 Jul;84(14):7396-404. doi: 10.1128/JVI.00056-10. Epub 2010 May 12.

8.
9.

HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC.

Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, Shaw GM, Hahn BH, Korber B, Seoighe C.

PLoS Pathog. 2009 May;5(5):e1000414. doi: 10.1371/journal.ppat.1000414. Epub 2009 May 8.

10.

Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance.

Jern P, Russell RA, Pathak VK, Coffin JM.

PLoS Pathog. 2009 Apr;5(4):e1000367. doi: 10.1371/journal.ppat.1000367. Epub 2009 Apr 3.

11.

RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1.

Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH.

PLoS Pathog. 2009 Mar;5(3):e1000330. doi: 10.1371/journal.ppat.1000330. Epub 2009 Mar 6.

12.

APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression.

Vázquez-Pérez JA, Ormsby CE, Hernández-Juan R, Torres KJ, Reyes-Terán G.

Retrovirology. 2009 Mar 2;6:23. doi: 10.1186/1742-4690-6-23.

13.

Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G.

Furukawa A, Nagata T, Matsugami A, Habu Y, Sugiyama R, Hayashi F, Kobayashi N, Yokoyama S, Takaku H, Katahira M.

EMBO J. 2009 Feb 18;28(4):440-51. doi: 10.1038/emboj.2008.290. Epub 2009 Jan 15.

14.

APOBEC3G inhibits elongation of HIV-1 reverse transcripts.

Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH.

PLoS Pathog. 2008 Dec;4(12):e1000231. doi: 10.1371/journal.ppat.1000231. Epub 2008 Dec 5.

15.

APOBEC proteins and intrinsic resistance to HIV-1 infection.

Malim MH.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):675-87. doi: 10.1098/rstb.2008.0185. Review.

16.

Evidence of a novel RNA secondary structure in the coding region of HIV-1 pol gene.

Wang Q, Barr I, Guo F, Lee C.

RNA. 2008 Dec;14(12):2478-88. doi: 10.1261/rna.1252608. Epub 2008 Oct 30.

17.

The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.

Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, Kanki PJ.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1285-90. doi: 10.1089/aid.2008.0072.

18.

Enhancing immunity to HIV through APOBEC.

Harris RS.

Nat Biotechnol. 2008 Oct;26(10):1089-90. doi: 10.1038/nbt1008-1089. No abstract available.

PMID:
18846074
19.

Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.

Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, Kramer B, McMichael AJ, Rambaut A, Iversen AK.

J Virol. 2008 Sep;82(17):8743-61. doi: 10.1128/JVI.00584-08. Epub 2008 Jun 18.

20.

Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya.

Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, Wachihi C, Kimani J, Plummer FA.

J Virol. 2008 Aug;82(16):8172-82. doi: 10.1128/JVI.01115-08. Epub 2008 Jun 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk